Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Gary Li is a principal scientist who leads the LC-MS protein characterization group at Aptevo Therapeutics, Seattle. He has worked in the biopharmaceutical industry for over 20 years and focuses on analytical/bioanalytical development and protein characterization. At Aptevo, he participates in activities of construct lead and clone selection, process intermediates and DS analytical development, technique transfer, and IND filing. He holds a BS in Analytical Chemistry and a PhD in Biophysics and Bioanalysis.
Analytical Characterization Strategy utilizing Mass Spectrometry for Construct Screening at Early Stage to Minimize Potential CMC Challenges
LC-MS is a powerful protein characterization tool that can be used to identify post-translational modifications (PTMs) on proteins during the clone selection process. An early read on product quality during clone selection can help avoid CMC pitfalls that can result in costly delays. PTMs can be sequence-dependent and by identifying these PTMs during the sequence optimization stage, enables the selection of constructs with more desirable product quality attributes. Four examples will be shown that highlight the use of mass spectrometry to confirm the presence of expected PTMs such as N-glycosylation of the Fc region in mAb-like molecules, as well as to screen out undesirable PTMs such as proline hydroxylation. These case studies demonstrate that in-depth characterization using mass spectrometry early in the development process can mitigate potential CMC risks and enable the product development and IND timelines to stay on track. 1. Identification of N-terminal pyroglutamate formation – an expected PTM 2. Cleavage site identification to minimize cleavages and increase protein yield 3. Proline hydroxylation PTM – an undesirable PTM 4. O-glycan PTM identification — selecting constructs with low levels of O-glycosylation for reducing manufacturing risk